著者

Yang Fu Bo Liu Hui Lei Zhenping Lin JunPeng Chen Yongwen Zhu Hui Ye Lin Yang Wence Wang

出版者

Japan Poultry Science Association

雑誌

The Journal of Poultry Science (ISSN:13467395)

巻号頁・発行日

vol.60, no.2, pp.2023008, 2023 (Released:2023-02-09)

参考文献数

29

被引用文献数

2

---

Abstract: Although the nutrient requirements of geese during the growing stage are known, the dietary requirement of amino acids during the starting period remains unclear. Optimum nutrient supplementation during the starting period is crucial for improved survival rates, body-weight gain, and marketing weight in geese. Our study focused on the effect of dietary tryptophan (Trp) supplementation on the growth performance, plasma parameters, and internal-organ relative weights in 1–28-day-old Sichuan white geese. A total of 1080 1-day-old geese were divided randomly into six Trp-supplemented (0.145%, 0.190%, 0.235%, 0.280%, 0.325%, and 0.370%) groups. Average daily feed intake (ADFI), average daily gain (ADG), and duodenal relative weight were highest in the 0.190% group, brisket protein level and jejunal relative weight in the 0.235% group, and plasma total protein and albumin levels in the 0.325% group (P < 0.05). Dietary Trp supplementation did not significantly affect the relative weights of the spleen, thymus, liver, bursa of Fabricius, kidneys, and pancreas. Moreover, the 0.145% – 0.235% groups showed significantly decreased liver fat (P < 0.05). Based on the non-linear regression analysis of ADG and ADFI, the dietary Trp levels between 0.183% and 0.190% were estimated to be optimal for 1–28-day-old Sichuan white geese. In conclusion, optimal dietary Trp supplementation in 1–28-day-old Sichuan white geese resulted in increased growth performance (0.180% – 0.190%) along with improved proximal intestinal development and brisket protein deposition (0.235%). Our findings provide basic evidence and guidance for optimal levels of Trp supplementation in geese.

著者

Yan Hao Yu-lin Yang Yong-chao Wang Jian Li

出版者

International Heart Journal Association

雑誌

International Heart Journal (ISSN:13492365)

巻号頁・発行日

pp.22-052, (Released:2022-07-14)

参考文献数

22

被引用文献数

13

---

Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors significantly reduce low-density lipoprotein cholesterol (LDL-C) and improve the prognosis of patients with acute coronary syndrome (ACS). However, the feasibility and safety of early application of PCSK9 inhibitors on the basis of statins combined with ezetimibe to strengthen lipid lowering in extremely high-risk coronary heart disease populations are still unknown.This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina. Adverse reactions included allergies, myalgia, poor blood glucose control, and liver damage.Within 1 month, the average level of LDL-C in the evolocumab group decreased from 3.54 to 0.57 mmol/L and that in the control group decreased from 3.52 to 1.26 mmol/L. The LDL-C compliance (< 1.0 mmol/L) rate was significantly increased in the evolocumab group compared with the control group (82.35% versus 22.06%, P < 0.01). The average level of lipoprotein (a) (Lp (a)) in the control group increased by 9.94 ± 51.93% from baseline after treatment, but evolocumab reduced the Lp (a) level (−38.84 ± 32.40%). Additionally, evolocumab further reduced the levels of apolipoprotein B/A1 (−70.56 ± 22.38% versus −51.29 ± 18.14%), cholesterol (−54.76 ± 18.10% versus −41.16 ± 18.14%), and apolipoprotein B (−66.47 ± 26.89% versus −46.78 ± 24.12%) compared with those in the control group, all P < 0.01. The blood lipid levels of both control and evolocumab groups stabilized after 1 month. During the 3-month follow-up, the incidence of MACEs after PCI was lower in the evolocumab group than in the control group (8.82% versus 24.59%, P = 0.015), and evolocumab combined with statins and ezetimibe did not increase the occurrence of adverse reactions (13.24% versus 11.48%, P = 0.762).In patients with extremely high-risk ACS with high levels of LDL-C, adding evolocumab to their treatment regimen as early as possible may enhance lipid lowering, increase the patient's LDL-C compliance rate in the short term, and improve cardiovascular prognosis but will not increase adverse reactions.